DE69739233D1 - Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff - Google Patents

Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff

Info

Publication number
DE69739233D1
DE69739233D1 DE69739233T DE69739233T DE69739233D1 DE 69739233 D1 DE69739233 D1 DE 69739233D1 DE 69739233 T DE69739233 T DE 69739233T DE 69739233 T DE69739233 T DE 69739233T DE 69739233 D1 DE69739233 D1 DE 69739233D1
Authority
DE
Germany
Prior art keywords
antigen
carrier
preparations
immunogenic
way
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739233T
Other languages
English (en)
Inventor
Nico Johannes Christiaan Maria Beekman
Wilhelmus Martinus Maria Schaaper
Kristian Dalsgaard
Robert Hans Meloen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pepscan Systems BV
Original Assignee
Pepscan Systems BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepscan Systems BV filed Critical Pepscan Systems BV
Application granted granted Critical
Publication of DE69739233D1 publication Critical patent/DE69739233D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE69739233T 1996-06-25 1997-06-24 Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff Expired - Lifetime DE69739233D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201766 1996-06-25
PCT/NL1997/000354 WO1997049425A1 (en) 1996-06-25 1997-06-24 Vaccine comprising antigens bound to carriers through labile bonds

Publications (1)

Publication Number Publication Date
DE69739233D1 true DE69739233D1 (de) 2009-03-12

Family

ID=8224113

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739233T Expired - Lifetime DE69739233D1 (de) 1996-06-25 1997-06-24 Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff

Country Status (10)

Country Link
EP (1) EP0912195B1 (de)
JP (1) JP4651753B2 (de)
AT (1) ATE421331T1 (de)
AU (1) AU732085B2 (de)
BR (1) BR9709993A (de)
CA (1) CA2260761C (de)
DE (1) DE69739233D1 (de)
DK (1) DK0912195T3 (de)
NZ (1) NZ333562A (de)
WO (1) WO1997049425A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
IL129177A0 (en) * 1996-09-26 2000-02-17 Univ Southern California Methods and compositions for lipidization of hydrophilic molecules
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
JP2004528321A (ja) 2001-04-04 2004-09-16 ノルディック ワクチン テクノロジー アクティーゼルスカブ ステロールおよびサポニンを含むポリヌクレオチド結合複合体
AU2003243663A1 (en) * 2002-06-20 2004-01-06 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
EP2358739A1 (de) * 2008-11-18 2011-08-24 The University Of Queensland Peptidkonjugate zur unterdrückung einer immunreaktion, herstellungsverfahren dafür und ihre verwendung
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
NL8900726A (nl) * 1989-03-23 1990-10-16 Stichting Centr Diergeneeskund Peptide, immunogene samenstelling en vaccin- of geneesmiddelpreparaat; werkwijze voor het immuniseren van een zoogdier tegen lhrh, en werkwijze voor het verbeteren van de vleeskwaliteit van varkens.
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
DE4101394A1 (de) * 1991-01-18 1992-07-23 Medor Lab Fuer Biochemie Und K Verfahren zum koppeln von kohlenhydraten an traeger, insbesondere proteine
ATE191147T1 (de) * 1991-07-26 2000-04-15 Commw Scient Ind Res Org System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
WO1994017098A1 (es) * 1993-01-23 1994-08-04 Inmunologia Y Genetica Aplicada, S.A. Peptidos y vacunas sinteticos contra parvovirus
EP0708656B1 (de) * 1993-04-27 2002-07-31 United Biomedical, Inc. Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法

Also Published As

Publication number Publication date
BR9709993A (pt) 1999-08-10
ATE421331T1 (de) 2009-02-15
CA2260761C (en) 2011-05-03
EP0912195A1 (de) 1999-05-06
EP0912195B1 (de) 2009-01-21
WO1997049425A1 (en) 1997-12-31
AU732085B2 (en) 2001-04-12
AU3193897A (en) 1998-01-14
JP4651753B2 (ja) 2011-03-16
CA2260761A1 (en) 1997-12-31
DK0912195T3 (da) 2009-05-18
JP2000513353A (ja) 2000-10-10
NZ333562A (en) 2001-04-27

Similar Documents

Publication Publication Date Title
WO1995029193A3 (en) Melanoma antigens
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
DK0941315T3 (da) Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner
DE69918146D1 (de) Verfahren zur therapeutischen impfung
EP2311952A3 (de) Antikörper gegen MART-1 Protein oder Fragmenten davon
ATE121782T1 (de) Rekombinante vakzine von flagellin.
DE69739233D1 (de) Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
CA2912496C (en) Immunogenic composition for use in therapy
WO2003088995A3 (en) Mucin fusion polypeptide vaccines, compositions and methods of use thereof
WO2005007673A3 (en) Immunogenic peptides
DE69534382D1 (de) Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind
DK218886D0 (da) Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
US8153135B2 (en) Polysaccharide-polypeptide conjugate
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
BR0013574A (pt) Antìgeno vacina de moraxella
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
DE60016806D1 (de) Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen
Lovgren Construction and potential of the iscom as immunogen.
DE69322960D1 (de) Empfängnisverhütender impfstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition